To the Editor. —
We have read Paul Cotton's excellent review article, "New Approaches May Aid Patients With Inflammatory Bowel Disease,"1 and we would like to report our preliminary results with interferon alpha-2a (Roferon-A/Roche) for treating children with severe, therapy-refractive inflammatory bowel disease: one girl with ulcerative colitis and two boys with Crohn's disease.The patients have received 3 million U of interferon alpha-2a subcutaneously three times a week for a period of 4 to 6 months. The treatment significantly ameliorated the clinical symptoms in all patients: urgency and bloody diarrhea, as well as abdominal pains after 4 weeks. The girl with ulcerative colitis is now in full remission with normal bowel movements and no bloody diarrhea and has a normal life-style. Both boys with Crohn's disease have gained weight, and their perianal fistulas have healed with their achievement of complete clinical and histological remission.The rationale for treating
Hadziselimovic F, Emmons LR. New Approaches for Inflammatory Bowel Disease. JAMA. 1990;264(21):2741. doi:10.1001/jama.1990.03450210036025
Customize your JAMA Network experience by selecting one or more topics from the list below.